

AMENDMENTS TO THE CLAIMS

Please cancel ~~claims~~ 22 through 47.

Please add the following new claims 56-81:

--56. A method of treating multiple sclerosis in a patient in need thereof by administering to said patient an effective amount of a peptide of from about 8 to about 25 amino acids having a sequence contained within amino acid residues 61-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

57. The method of Claim 56, wherein the peptide has a sequence contained within amino acid residues 75-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

B4  
58. The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 80-97 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

59. The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 82-99 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

60. The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 84-93, 85-94, 86-95, or 87-96 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

61. The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 91-106 of SEQ ID NO:1, including substitutions, additions or deletions

thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

62. The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 75-95 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

63. The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 64-78 of SEQ ID NO:1, including substitutions, additions or deletions thereof, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

64. The method of Claim 56 wherein the peptide is administered in admixture with a pharmaceutical acceptable carrier.

65. The method of Claim 56 wherein the peptide is administered intravenously or intrathecally, or in combination.

66. The method of Claim 56 wherein the peptide is administered as a single or sequential dose.

67. The method of Claim 56 wherein the patient has chronic progressive MS.

68. The method of Claim 56 wherein the patient has an acute MS relapse.

69. A method of reducing free anti-myelin basic protein in a patient in need thereof by administering to said patient an effective amount of a peptide of from about 8 to about 25 amino acids and having a sequence contained within amino acid residues 61-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

70. The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 75-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

71. The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 80-97 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

72. The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 82-99 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

73. The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 84-93, 85-94, 86-95, or 87-96 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

74. The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 91-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

B4  
75. The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 75-95 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

76. The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 64-78 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

77. The method of Claim 69 wherein the peptide is administered in admixture with a pharmaceutical acceptable carrier.

78. The method of Claim 69 wherein the peptide is administered intravenously or intrathecally, or in combination.

79. The method of Claim 69 wherein the peptide is administered as a single or sequential dose.

80. The method of Claim 69 wherein the patient has chronic progressive MS.

81. The method of Claim 69 wherein the patient has an acute MS relapse.--

### **Complete Listing of Claims**

Claims 1-47 (cancelled).

Claims 48-55 (withdrawn).

Claim 56 (new): A method of treating multiple sclerosis in a patient in need thereof by administering to said patient an effective amount of a peptide of from about 8 to about 25 amino acids having a sequence contained within amino acid residues 61-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 57 (new): The method of Claim 56, wherein the peptide has a sequence contained within amino acid residues 75-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 58 (new): The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 80-97 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 59 (new): The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 82-99 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 60 (new): The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 84-93, 85-94, 86-95, or 87-96 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 61 (new): The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 91-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 62 (new): The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 75-95 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 63 (new): The method of Claim 56 wherein the peptide has a sequence contained within amino acid residues 64-78 of SEQ ID NO:1, including substitutions, additions or deletions thereof, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 64 (new): The method of Claim 56 wherein the peptide is administered in admixture with a pharmaceutical acceptable carrier.

Claim 65 (new): The method of Claim 56 wherein the peptide is administered intravenously or intrathecally, or in combination.

Claim 66 (new): The method of Claim 56 wherein the peptide is administered as a single or sequential dose.

Claim 67 (new): The method of Claim 56 wherein the patient has chronic progressive MS.

Claim 68 (new): The method of Claim 56 wherein the patient has an acute MS relapse.

Claim 69 (new): A method of reducing free anti-myelin basic protein in a patient in need thereof by administering to said patient an effective amount of a peptide of from about 8 to about 25 amino acids and having a sequence contained within amino acid residues 61-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 70 (new): The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 75-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 71 (new): The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 80-97 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 72 (new): The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 82-99 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 73 (new): The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 84-93, 85-94, 86-95, or 87-96 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 74 (new): The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 91-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 75 (new): The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 75-95 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 76 (new): The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 64-78 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 77 (new): The method of Claim 69 wherein the peptide is administered in admixture with a pharmaceutical acceptable carrier.

Claim 78 (new): The method of Claim 69 wherein the peptide is administered intravenously or intrathecally, or in combination.

Claim 79 (new): The method of Claim 69 wherein the peptide is administered as a single or sequential dose.

Claim 80 (new): The method of Claim 69 wherein the patient has chronic progressive MS.

Claim 81 (new): The method of Claim 69 wherein the patient has an acute MS relapse.